Allergy Shots for Adults: Efficacy Across All Ages and Life Stages

It is not too late to start allergy shots as an adult. Adults of all ages benefit from immunotherapy, and there is no established upper age limit for SCIT eligibility based on age alone. Bozek et al.'s 2016 double-blind randomized trial specifically demonstrated efficacy in patients aged 60-75 with grass pollen allergic rhinitis, showing significant symptom and medication score reductions comparable to younger populations. The key eligibility criteria are the same for adults and children: documented IgE-mediated sensitization to clinically relevant allergens and symptoms occurring upon allergen exposure. Comorbidities, medications, and overall health are individually assessed — age itself is not a disqualifying factor.

Beta-blockers are considered a relative contraindication for SCIT because they can impair the body's epinephrine response if a systemic reaction occurs. However, contemporary data from Sturm et al. (2021, n=1,425) showed that beta-blocker and ACE inhibitor use did NOT significantly increase adverse event rates during venom immunotherapy compared to non-users. The 2023 Anaphylaxis Practice Parameter update softened the position toward shared decision-making when cardiac indications for beta-blockers are compelling. For patients on ACE inhibitors, current guidance also favors individualized assessment over blanket contraindication. Discuss your specific medications with your allergist before starting — in many cases, the benefits of continuing cardiac medications outweigh the theoretical increase in reaction risk, especially for well-controlled patients.

Most adults notice meaningful symptom improvement within 6-12 months of starting allergy shots, typically once they have reached and sustained the maintenance dose. The AAAAI/ACAAI Practice Parameter states that clinical improvement is usually observed within one year of reaching maintenance. Some patients notice earlier benefit during the build-up phase as partial desensitization occurs. Full disease-modifying benefit — the sustained improvement that persists years after stopping — requires completing the minimum recommended 3-year treatment course. If no benefit is evident after one year at maintenance dose, the allergist should reassess allergen selection, dosing adequacy, and whether environmental allergen load is overwhelming the treatment effect.

Yes, allergy shots can effectively treat adult-onset allergies as well as longstanding childhood allergies that persist into adulthood. Adult-onset allergic rhinitis is common and can develop from new environmental exposures, changes in immune regulation with aging, or de novo sensitization to previously tolerated allergens. The mechanism of SCIT — inducing allergen-specific regulatory T cells and IgG4 blocking antibodies — functions the same regardless of when the allergy developed. The most important eligibility requirement is demonstrating IgE-mediated sensitization through skin testing or specific IgE blood testing, which your allergist will confirm before developing a treatment protocol. Adults with new-onset symptoms should see a board-certified allergist to identify the specific triggers before beginning any immunotherapy.

A complete adult allergy shot course involves approximately 60-100+ injections over 3-5 years. During the build-up phase (3-6 months), adults receive 1-2 injections per week for a total of roughly 25-30 injections to reach the maintenance dose. Once maintenance is reached, injections shift to every 2-4 weeks for 3-5 years, adding approximately 35-75 more injections. Each visit requires a 30-minute post-injection observation period, so a typical maintenance visit consumes about 45 minutes of clinic time. Total patient time over a 3-5 year course, including travel and waiting, has been estimated at 60-165 hours — a meaningful commitment that many adults weigh against the long-term disease-modifying benefit.

Allergy shots can address both indoor (perennial) and outdoor (seasonal) allergens in the same treatment program. For adults who are sensitized to multiple allergens — a common pattern called polysensitization — US allergists typically prepare a custom multi-allergen vial containing the relevant extracts. The evidence for single-allergen programs (grass, dust mites) is strongest, but multi-allergen mixes targeting the dominant triggers are routine in US practice. Your allergist will perform comprehensive allergy testing to map which allergens are actually causing your symptoms, distinguishing true sensitization from cross-reactivity. Indoor perennial allergens like dust mites and cat dander are particularly suitable for immunotherapy because avoidance is impractical in most living situations.

Adults with mild to moderate, well-controlled allergic asthma can receive allergy shots, and the evidence supports symptom and medication reductions. However, uncontrolled or severe asthma is a relative-to-absolute contraindication — most guidelines use FEV1 below 70% of predicted as the threshold requiring caution or deferral. This precaution exists because uncontrolled asthma is the dominant risk factor for severe and fatal SCIT reactions, accounting for 4 of the 7 confirmed SCIT fatalities in the 2013-2017 surveillance period. Before each injection, your allergist should assess whether asthma is currently well controlled. Adults with allergic asthma driven by dust mites or pollens may benefit substantially — the Cochrane review of 88 asthma SCIT trials found symptom score reductions of SMD -0.59 with NNT of 3 to prevent one symptom deterioration.